Combined Therapy with Levothyroxine and Liothyronine in Two Ratios, Compared with Levothyroxine Monotherapy in Primary Hypothyroidism: a Double-Blind, Randomized, Controlled Clinical Trial
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Controversy remains about the value of combined treatment with levothyroxine (LT4) and liothyronine (LT3), compared with LT4 alone in primary hypothyroidism. We compared combined treatment with LT4 and LT3 in a ratio of 5:1 or 10:1 with LT4 monotherapy. We conducted a double-blind, randomized, controlled trial in 141 patients (18-70 yr old) with primary autoimmune hypothyroidism, recruited via general practitioners. Inclusion criteria included: LT4 treatment for 6 months or more, a stable dose for 6 wk or more, and serum TSH levels between 0.11 and 4.0 microU/ml (mU/liter). Randomization groups were: 1) continuation of LT4 (n = 48); 2) LT4/LT3, ratio 10:1 (n = 46); and 3) LT4/LT3, ratio 5:1 (n = 47). Subjective preference of study medication after 15 wk, compared with usual LT4, was the primary outcome measure. Secondary outcomes included scores on questionnaires on mood, fatigue, psychological symptoms, and a substantial set of neurocognitive tests. Study medication was preferred to usual treatment by 29.2, 41.3, and 52.2% in the LT4, 10:1 ratio, and 5:1 ratio groups, respectively (chi2 test for trend, P = 0.024). This linear trend was not substantiated by results on any of the secondary outcome measures: scores on questionnaires and neurocognitive tests consistently ameliorated, but the amelioration was not different among the treatment groups. Median end point serum TSH was 0.64 microU/ml (mU/liter), 0.35 microU/ml (mU/liter), and 0.07 microU/ml (mU/liter), respectively [ANOVA on ln(TSH) for linear trend, P < 0.01]. Mean body weight change was +0.1, -0.5, and -1.7 kg, respectively (ANOVA for trend, P = 0.01). Decrease in weight, but not decrease in serum TSH was correlated with increased satisfaction with study medication. Of the patients who preferred combined LT4/LT3 therapy, 44% had serum TSH less than 0.11 microU/ml (mU/liter). Patients preferred combined LT4/LT3 therapy to usual LT4 therapy, but changes in mood, fatigue, well-being, and neurocognitive functions could not satisfactorily explain why the primary outcome was in favor of LT4/LT3 combination therapy. Decrease in body weight was associated with satisfaction with study medication.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For the parallel design trials, there was a preference for combination therapy in one trial of 130 patients (53)”
From Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document (2021) · cites this paper as [53]
In the citing paper
“In the LT4/LT3 study of Appelhof et al. (53), no significant change in the PRO used was seen, but patients more frequently expressed a preference for the combination.”
From Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document (2021) · cites this paper as [53]
In the citing paper
“This was not achieved in five trials, with two trials having a lower TSH in the combination therapy group (including the Appelhof trial in 5:1 ratio group) (53,71), and three trials having a higher serum TSH in the combination therapy group (47,52,58).”
From Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document (2021) · cites this paper as [53]
In the citing paper
“Eleven trials were 5–16 weeks (23,46,49,51–53,58–60,71,79), three trials were 4–6 months (17,48,78), and one trial was 1 year in duration (47).”
From Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document (2021) · cites this paper as [53]
In the citing paper
“Two trials showed a decreased cholesterol in the combination therapy arm (53,78), while a third trial showed an increased cholesterol in the combination therapy group, but this group also had a higher mean TSH value (52).”
From Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document (2021) · cites this paper as [53]
27 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Smets, E. M. A., Garssen, B., Bonke, B., & De Haes, J. C. J. M. (1995) · Journal of Psychosomatic Research · doi:10.1016/0022-3999(94)00125-o · Cited by 3,613
Aaronson, N. K., Muller, M., Cohen, P. D. A., Essink-Bot, M.-L., Fekkes, M., Sanderman, R., Sprangers, M. A. G., te Velde, A., & Verrips, E. (1998) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(98)00097-3 · Cited by 2,276
Werner & Ingbar's the thyroid : a fundamental and clinical text
Werner, S. C., Ingbar, S. H., Braverman, L. E., & Utiger, R. D. (2012) · Lippincott-Raven eBooks · Cited by 1,016
Rivermead Behavioural Memory Test: Præsentation og vurdering af en ny psykologisk prøve
COUR, P. L., & GALLAGHER, K. (1990) · Nordisk Psykologi · doi:10.1080/00291463.1990.10636996 · Cited by 988
Are randomized clinical trials good for us (in the short term)? Evidence for a “trial effect”
Braunholtz, D. A., Edwards, S. J. L., & Lilford, R. J. (2001) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(00)00305-x · Cited by 539
Saravanan, P., Chau, W. ‐., Roberts, N., Vedhara, K., Greenwood, R., & Dayan, C. M. (2002) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2002.01654.x · Cited by 514 · cited 3×
“It has been noted before that many hypothyroid patients find their physicians to be unsympathetic and dismissive of their symptoms (1), which may explain the extent of these aspecific trial effects in this study investigating the possibility to relief these uncomprehended complaints.”
BackgroundInfluentialBunevičius, R., Kažanavičius, G., Žalinkevičius, R., & Prange, A. J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902113400603 · Cited by 482 · cited 2×
“5 g LT3 daily resulted in improved scores on mood scales and neurocognitive tests (4).”
BackgroundThe psychological effects of concussion
Gronwall, D., & Sampson, H. (1974) · Cited by 289
Escobar-Morreale, H. F., Obregón, M. J., Escobar del Rey, F., & Morreale de Escobar, G. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118353 · Cited by 287
The Psychological Effects of Concussion
Walsh, K. W. (1975) · Medical Journal of Australia · doi:10.5694/j.1326-5377.1975.tb106128.x · Cited by 285
Escobar-Morreale, H. F., del Rey, F. E., Obregón, M. J., & de Escobar, G. M. (1996) · Endocrinology · doi:10.1210/endo.137.6.8641203 · Cited by 261 · cited 1×
“is able to maintain T3 homeostasis over a wide range of plasma T4 and T3 levels (2, 3).”
BackgroundPeeters, R. P., van Toor, H., Klootwijk, W., de Rijke, Y. B., Kuiper, G. G. J. M., Uitterlinden, A. G., & Visser, T. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021592 · Cited by 243
CARR, D., MCLEOD, D. T., PARRY, G., & THORNES, H. M. (1988) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1988.tb01219.x · Cited by 210
Walsh, J. P., Shiels, L., Lim, E. M., Bhagat, C. I., Ward, L. C., Stuckey, B. G. A., Dhaliwal, S. S., Chew, G. T., Bhagat, M. C., & Cussons, A. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030249 · Cited by 210
Clyde, P. W., Harari, A. E., Getka, E. J., & Shakir, K. M. M. (2003) · JAMA · doi:10.1001/jama.290.22.2952 · Cited by 195 · cited 7×
“LT4 in Primary Hypothyroidism J Clin Endocrinol Metab, May 2005, 90(5):2666–2674 2667”
BackgroundInfluentialDeficits of Attention after Closed-Head Injury: Slowness Only?
Spikman, J. M., Zomeren, A. H. V., & Deelman, B. G. (1996) · Journal of Clinical and Experimental Neuropsychology · doi:10.1080/01688639608408298 · Cited by 187
Pilo, A., Iervasi, G., Vitek, F., Ferdeghini, M., Cazzuola, F., & Bianchi, R. (1990) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1990.258.4.e715 · Cited by 185
Sawka, A. M., Gerstein, H. C., Marriott, M. J., MacQueen, G. M., & Joffe, R. T. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030139 · Cited by 175 · cited 1×
“80 Positive TPO-ab (n, %) 38 (79) 37 (80) 36 (78) Current major depressive disorder (n, %) 3 (6) 4 (9) 3 (7)”
Siegmund, W., Spieker, K., Weike, A. I., Giessmann, T., Modess, C., Dabers, T., Kirsch, G., Sänger, E., Engel, G., Hamm, A. O., et al. (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.02050.x · Cited by 152
A RADIOIMMUNOASSAY OF THYROXINE
CHOPRA, I. J., SOLOMON, D. H., & HO, R. S. (1971) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-33-5-865 · Cited by 134
Information processing in depression and anxiety
Brand, N., & Jolles, J. (1987) · Psychological Medicine · doi:10.1017/s0033291700013040 · Cited by 125
Wiersinga, W. M., & CHOPRA, I. J. (1982) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/0076-6879(82)84024-x · Cited by 113
Self-citationHennemann, G., Docter, R., Visser, T. J., Postema, P. T., & Krenning, E. P. (2004) · Thyroid · doi:10.1089/105072504323030924 · Cited by 90
Spectrum of quality of life impairment in hypothyroidism
Jaeschke, R., Guyatt, G. H., Cook, D., Harper, S., & Gerstein, H. C. (1994) · Quality of Life Research · doi:10.1007/bf00451724 · Cited by 82
Bunevicius, R., & Prange, A. J. (2000) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145700001826 · Cited by 78
Monitoring Therapy in Patients Taking Levothyroxine
Helfand, M., & Crapo, L. M. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-113-6-450 · Cited by 62
Kaplan, M. M., Sarne, D. H., & Schneider, A. B. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031436 · Cited by 56
Cognitive Ergonomics, Clinical Assessment and Computer-Assisted Learning
den Brinker, B. P. L. M., Beek, P. J., Brand, A. N., Maarse, F. J., & Mulder, L. J. M. (1999) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 42
Wartofsky, L. (2004) · Thyroid · doi:10.1089/105072504323030898 · Cited by 22
Al‐Abadi, A. (2001) · Postgraduate Medical Journal · doi:10.1136/pmj.77.903.29 · Cited by 16
Cited by
Jonklaas, J., Bianco, A. C., Bauer, A. J., Burman, K. D., Cappola, A. R., Celi, F. S., Cooper, D. S., Kim, B. W., Peeters, R. P., Rosenthal, M. S., et al. (2014) · Thyroid® · doi:10.1089/thy.2014.0028 · Cited by 1,928
“We included three studies on secondary analyses (390,540,541) stemming from two prospective trials comparing LT4/LT3 combination therapy to LT4 alone in primary hypothyroidism (386,522) in our review.”
InfluentialChaker, L., Bianco, A. C., Jonklaas, J., & Peeters, R. P. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30703-1 · Cited by 1,159
2012 ETA Guidelines: The Use of L-T4 + L-T3 in the Treatment of Hypothyroidism
Wiersinga, W. M., Duntas, L., Fadeyev, V., Nygaard, B., & Vanderpump, M. P. J. (2012) · European Thyroid Journal · doi:10.1159/000339444 · Cited by 437
Self-citationDeiodinases and their intricate role in thyroid hormone homeostasis
Luongo, C., Dentice, M., & Salvatore, D. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0218-2 · Cited by 332
Chaker, L., Razvi, S., Bensenor, I. M., Azizi, F., Pearce, E. N., & Peeters, R. P. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00357-7 · Cited by 330
Metadata
- Authors
- Appelhof, B. C., Fliers, E., Wekking, E. M., Schene, A. H., Huyser, J., Tijssen, J. G. P., Endert, E., van Weert, H. C. P. M., & Wiersinga, W. M.
- Affiliations
- Amsterdam UMC Location University of Amsterdam (NL)
- Corresponding author
- Appelhof, Bente C.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2005-05
- Volume
- 90
- Issue
- 5
- Pages
- 2666-2674
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2140933987
- Cited by
- 183
- References
- 30
- Citations by year
- 2026: 3 · 2025: 12 · 2024: 7 · 2023: 5 · 2022: 9 · 2021: 11 · 2020: 10 · 2019: 9 · 2018: 13 · 2017: 7 · 2016: 13 · 2015: 7 · 2014: 7 · 2013: 5 · 2012: 11
- FWCI
- 6.83
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
- Keywords
- primary hypothyroidism, levothyroxine, liothyronine, T3/T4 ratio, thyroid-stimulating hormone, treatment satisfaction, body weight, fatigue, mood, neurocognitive function, autoimmune hypothyroidism, patient preferences, TSH suppression
- MeSH terms
- Adolescent, Adult, Aged, Cognition, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Hypothyroidism, Male, Middle Aged, Thyrotropin, Thyroxine, Triiodothyronine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.